Author

Manon Laporte

Rega Institute for Medical ResearchPrimary ORCID profile (0000-0001-5708-1321 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Manon LaporteiD1 paper · Rega Institute for Medical Research

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:rat· 1 Organism:virus· 1

Frequent Co-Authors

Johan H. NeytsiD· 2 shared A. Kenneth MacLeodiD· 1 shared Alpha A. LeeiD· 1 shared Andrew Wells· 1 shared Annette von DelftiD· 1 shared Anthony Simon· 1 shared Benjamin PerryiD· 1 shared Bert VanmecheleniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Johan H. NeytsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

4'-fluorouridine is a potent inhibitor of Oropouche virus in vitro and in animal infection models

Martin Ferrié, Maïlis Darmuzey, Itona Tarillon, Thibault Tubiana, Mona Khan, Tania Roskams, Birgit Weynand, Dietmar Rudolf Thal, Niels Cremers, Stijn Hendrickx, Kim Donckers, Thayara Morais Portal, Bert Vanmechelen, Viktor Lemmens, Joana Rocha‐Pereira, , Johan H. Neyts

This study shows 4'-fluorouridine inhibits Oropouche virus replication in vitro and in animal models, with no resistant variants observed.

bioRxiv · Sep 22, 2025 · PreprintMicrobiology

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Ed Griffen, D. Fearon, Briana Lynn McGovern, L. Koekemoer, Blake H. Balcomb, Tamás Szommer, Gwendolyn Fate, Ralph P. Robinson, Bruce A. Lefker, Shirly Duberstein, Noa Lahav, Stéphanie Braillard, Laura Vangeel, Manon Laporte, Fabienne Burgat Charvillon, , Annette von Delft

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

bioRxiv · Jun 16, 2025 · PreprintPharmacology & Toxicology